Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2022 09:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Present at Upcoming Investor Conferences in November

DALLAS, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
October 24, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

UB-612 Phase 3 topline data readout expected in 4Q22 DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of...
September 13, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

DALLAS, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first...
September 12, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)

DALLAS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that it has...
September 01, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Present at Upcoming Investor Conferences in September

DALLAS, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
August 11, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates

• UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 • UB-312 Phase 1 Part B Trial for Parkinson’s Completes Last Patient Last Dose, and Remains...
August 04, 2022 07:00 ET | Source: Vaxxinity, Inc.

Vaxxinity to Present at the Canaccord Genuity 42nd Annual Growth Conference

DALLAS, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu,...
August 02, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity’s Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates

Results support Anti-PCSK9 vaccine approach to treat hypercholesterolemia by lowering LDL cholesterolVXX-401 selected as Lead Candidate to treat hypercholesterolemia DALLAS, Aug. 02, 2022 (GLOBE...
August 01, 2022 08:00 ET | Source: Vaxxinity, Inc.

Vaxxinity Presents Preclinical Data on Tau Vaccine Candidates at the 2022 Alzheimer's Association International Conference (AAIC)

DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, presented new preclinical data on...
July 25, 2022 11:57 ET | Source: Vaxxinity, Inc.

Vaxxinity CEO Mei Mei Hu Speaking at White House Summit on the Future of COVID-19 Vaccines

Summit is taking place July 26, 2022 from 11:00 AM ET – 3:15 PM ET The White House Summit on the Future of COVID-19 Vaccines live webcast can be accessed here DALLAS, July 25, 2022 (GLOBE...